MedTrace Logo

An Study of Aripiprazole in the Treatment of Methamphetamine Dependence

NCT01813656 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-02-04

No results posted yet for this study

Summary

Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. Aripiprazole are Second generation antipsychotics，but have different pharmacological effects of neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among mehtamphetamine addicts.

Conditions

  • Methamphetamine Dependence

Interventions

DRUG

Aripiprazole

Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks

DRUG

placebo

placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks

Sponsors & Collaborators

  • Wei Hao

    lead OTHER

Principal Investigators

  • Wei Hao, MD., Ph.D. · Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-12-31
Completion
2014-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01813656 on ClinicalTrials.gov